Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma.
Kim TM, Taszner M, Novelli S, Cho SG, Villasboas JC, Merli M, Jiménez-Ubieto A, Tessoulin B, Poon LM, Tucker D, Walewski J, Yi S, Song Y, Chong G, Bachy E, Guidez S, Alonso A, Jagadeesh D, Zhang W, Magnano L, Iskierka-Jażdżewska E, Tani M, Shen B, Uppala A, Zhu M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Luminari S; ELM-2 Investigators. Kim TM, et al. Among authors: brouwer visser j. Ann Oncol. 2024 Nov;35(11):1039-1047. doi: 10.1016/j.annonc.2024.08.2239. Epub 2024 Aug 13. Ann Oncol. 2024. PMID: 39147364 Free article. Clinical Trial.
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models.
Wei J, Montalvo-Ortiz W, Yu L, Krasco A, Olson K, Rizvi S, Fiaschi N, Coetzee S, Wang F, Ullman E, Ahmed HS, Herlihy E, Lee K, Havel L, Potocky T, Ebstein S, Frleta D, Khatri A, Godin S, Hamon S, Brouwer-Visser J, Gorenc T, MacDonald D, Hermann A, Chaudhry A, Sirulnik A, Olson W, Lin J, Thurston G, Lowy I, Murphy AJ, Smith E, Jankovic V, Sleeman MA, Skokos D. Wei J, et al. Among authors: brouwer visser j. Sci Transl Med. 2022 Nov 9;14(670):eabn1082. doi: 10.1126/scitranslmed.abn1082. Epub 2022 Nov 9. Sci Transl Med. 2022. PMID: 36350988
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Brouwer-Visser J, Fiaschi N, Deering RP, Cygan KJ, Scott D, Jeong S, Boucher L, Gupta NT, Gupta S, Adler C, Topp MS, Bannerji R, Duell J, Advani RH, Flink DM, Chaudhry A, Thurston G, Ambati SR, Jankovic V. Brouwer-Visser J, et al. J Immunother Cancer. 2024 Mar 21;12(3):e008338. doi: 10.1136/jitc-2023-008338. J Immunother Cancer. 2024. PMID: 38519055 Free PMC article.
Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047].
Kim TM, Taszner M, Novelli S, Cho SG, Villasboas JC, Merli M, Jiménez-Ubieto A, Tessoulin B, Poon LM, Tucker D, Walewski J, Yi S, Song Y, Chong G, Bachy E, Guidez S, Alonso A, Jagadeesh D, Zhang W, Magnano L, Iskierka-Jażdżwska E, Tani M, Shen B, Uppala A, Zhu M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Luminari S; ELM-2 Investigators. Kim TM, et al. Among authors: brouwer visser j. Ann Oncol. 2024 Dec 2:S0923-7534(24)04945-7. doi: 10.1016/j.annonc.2024.11.009. Online ahead of print. Ann Oncol. 2024. PMID: 39627085 Free article. No abstract available.
Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer.
Zhu M, Madia P, Crawford A, Brouwer-Visser J, Krueger P, Haber L, Peterman M, Uldrick TS, Miller E, Davis JD, Retter MW. Zhu M, et al. Among authors: brouwer visser j. Clin Transl Sci. 2024 Dec;17(12):e70082. doi: 10.1111/cts.70082. Clin Transl Sci. 2024. PMID: 39652449 Free PMC article.
Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
Weinstock M, Elavalakanar P, Bright S, Ambati SR, Brouwer-Visser J, Pourpe S, Fiaschi N, Jankovic V, Thurston G, Deering RP, Chaudhry A, Joyce R, Arnason J. Weinstock M, et al. Among authors: brouwer visser j. Br J Haematol. 2022 Nov;199(3):366-370. doi: 10.1111/bjh.18383. Epub 2022 Jul 27. Br J Haematol. 2022. PMID: 35892294 Free PMC article.
Immune contexture of paediatric cancers.
Thakur MD, Franz CJ, Brennan L, Brouwer-Visser J, Tam R, Korski K, Koeppen H, Ziai J, Babitzki G, Ranchere-Vince D, Vasiljevic A, Dijoud F, Marec-Bérard P, Rochet I, Cannarile MA, Marabelle A. Thakur MD, et al. Among authors: brouwer visser j. Eur J Cancer. 2022 Jul;170:179-193. doi: 10.1016/j.ejca.2022.03.012. Epub 2022 May 31. Eur J Cancer. 2022. PMID: 35660252
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.
Dickinson M, Briones J, Herrera AF, González-Barca E, Ghosh N, Cordoba R, Rutherford SC, Bournazou E, Labriola-Tompkins E, Franjkovic I, Chesne E, Brouwer-Visser J, Lechner K, Brennan B, Nüesch E, DeMario M, Rüttinger D, Kornacker M, Hutchings M. Dickinson M, et al. Among authors: brouwer visser j. Blood Adv. 2021 Nov 23;5(22):4762-4770. doi: 10.1182/bloodadvances.2021004619. Blood Adv. 2021. PMID: 34581757 Free PMC article. Clinical Trial.
21 results